The Fly | JUNS

Novel Mechanism of Action: JOTROL, their lead compound, targets neuroinflammation and mitochondrial dysfunction, offering a unique approach to neurological disorders beyond symptomatic treatment.

Broad Therapeutic Pipeline-in-a-Product Potential: JOTROL is being evaluated for multiple, diverse neurological indications, positioning it for significant market expansion if successful in one or more areas.

Addressing Significant Unmet Medical Needs: The company focuses on diseases like Alzheimer's, Parkinson's, and Friedreich's Ataxia, which currently have limited or no effective treatments, representing large patient populations and market opportunities.

Clinical Trial Outcomes Risk: Clinical development programs are uncertain and may fail to demonstrate safety or efficacy, leading to no product approval.

Regulatory Approval Uncertainty Risk: Even if clinical trials are successful, there is no guarantee that regulatory bodies will grant market approval for their product candidates.

Capital Needs and Dilution Risk: The company requires substantial additional funding to advance its pipeline and operations, which may lead to significant shareholder dilution.

Charts

Novel Mechanism of Action: JOTROL, their lead compound, targets neuroinflammation and mitochondrial dysfunction, offering a unique approach to neurological disorders beyond symptomatic treatment.

Clinical Trial Outcomes Risk: Clinical development programs are uncertain and may fail to demonstrate safety or efficacy, leading to no product approval.

Regulatory Approval Uncertainty Risk: Even if clinical trials are successful, there is no guarantee that regulatory bodies will grant market approval for their product candidates.

Capital Needs and Dilution Risk: The company requires substantial additional funding to advance its pipeline and operations, which may lead to significant shareholder dilution.